Skip to main content
BIOXYNE LIMITED logo

BIOXYNE LIMITED — Investor Relations & Filings

Ticker · BXN ISIN · AU000000BXN6 LEI · 984500F02D2B1B94E956 ASX Manufacturing
Open in API
Filings indexed 841 across all filing types
Latest filing 2026-03-19 Share Issue/Capital Cha…
Country AU Australia
Listing ASX BXN

About BIOXYNE LIMITED

https://bioxyne.com

Bioxyne Limited is a life sciences company focused on the development, manufacture, and commercialization of health and wellness products. The company specializes in proprietary probiotic strains, notably the Lactobacillus fermentum VRI-003 (PCC), which is utilized in supplements targeting immune health and gut function. Following the acquisition of Breathe Life Sciences, Bioxyne has expanded its portfolio into the medicinal cannabis sector, novel foods, and consumer health products. Its operations encompass the production and distribution of pharmaceutical-grade cannabis products, CBD-based wellness items, and functional supplements. The company serves international markets through a vertically integrated model, focusing on research-driven formulations and high-quality manufacturing standards to address growing consumer demand for therapeutic and preventative health solutions.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - BXN 6 pages 19.3KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an announcement from BIOXYNE LIMITED regarding the application for quotation of new securities on the ASX. It details the number and type of securities to be quoted, the circumstances of the issue (settlement of commission liability under a service agreement), and compliance with ASX listing rules. The document is an official announcement related to the issuance and quotation of shares, not a financial report or earnings release. It fits the category of Share Issue/Capital Change announcements, which cover new share issues and capital structure changes.
2026-03-19 English
Cleansing 2 pages 272.0KB
Regulatory Filings Classification · 95% confidence The document is a Cleansing Notice pursuant to Section 708A(5)(e) of the Corporations Act 2001, related to the issue of shares and compliance with disclosure obligations. It is a regulatory announcement about share issuance and compliance, not a financial report or detailed financial data. The document length is 3620 characters, which is relatively short and primarily contains a legal compliance notice rather than a full report. There is no financial statement or detailed analysis present. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-03-19 English
Application for quotation of securities - BXN 6 pages 18.2KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) announcement for the application for quotation of securities. It details the issuance and quotation of new securities resulting from options being exercised or convertible securities being converted. The document includes specifics such as the number of securities, issue date, and class of securities. This type of document is a formal announcement related to capital changes, specifically the issuance and quotation of new shares. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about share capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and content confirm it is not merely a brief notice but a full application form for quotation of securities.
2026-03-17 English
Half Yearly Report and Accounts 37 pages 6.6MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4D – Half Year Report' and explicitly states it is an 'INTERIM FINANCIAL REPORT FOR THE HALF-YEAR ENDED 31 DECEMBER 2025'. It contains detailed financial data including consolidated statements of profit or loss, financial position, cash flows, notes to financial statements, directors' report, and auditor's report. The reporting period is clearly a half-year period (1 July 2025 to 31 December 2025). The document length is substantial (15,000 characters) and contains actual financial statements and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2026
2026-02-25 English
Stronger H1 FY2026 Performance Upward Revision to Guidance 2 pages 380.7KB
Earnings Release Classification · 95% confidence The document is an announcement dated 26 February 2026 from Bioxyne Limited regarding an upgrade to its FY26 adjusted EBITDA guidance based on a stronger than expected first half performance. It includes key financial highlights such as H1 FY26 adjusted EBITDA and revenue figures, and updated full-year guidance. The document is relatively short (4414 characters) and focuses on financial performance updates and guidance revisions rather than providing a full comprehensive financial report or detailed financial statements. There is no indication that this is a full interim or annual report, nor is it a transcript, audit report, or other specific filing type. The content aligns with an Earnings Release (ER), which typically announces quarterly or half-year financial results and guidance highlights. Therefore, the appropriate classification is Earnings Release (ER). H1 2026
2026-02-25 English
BXN H1 FY2026 Results Presentation 17 pages 1.0MB
Investor Presentation Classification · 95% confidence The document is titled 'H1 FY2026 Results Presentation' and contains detailed financial data including revenue, EBITDA, profit before tax, balance sheet items, cash flow, and operational commentary for the half-year period ending December 2025. It includes forward-looking guidance for FY26 and strategic information about market expansion and manufacturing capacity. The content is structured as a presentation with charts and commentary, typical of an investor presentation. It is not a full annual report (10-K), nor a regulatory filing or earnings release in brief form. The document is comprehensive and focused on half-year financial results and business strategy, consistent with an Interim / Quarterly Report or an Investor Presentation. However, the format and style, including extensive strategic and operational details alongside financials, align more closely with an Investor Presentation (IP) rather than a formal Interim Report (IR). Therefore, the best classification is Investor Presentation (IP).
2026-02-25 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.